Rheumatic disease following immunotherapy

Sir: Articulargias and exacerbation of pre-existing arthritis are well known side effects of treatment with interferons and interleukin-2 (IL-2). 1-3 We report here, however, on two patients with malignant melanoma receiving immunotherapy who developed acute arthritis resembling anklyosing spondylitis and psoriatic arthropathy, respectively.

Since 1987 we have treated 64 patients with malignant melanoma with IL-2 and lymphokine activated killer cells. 4 In one of these patients our observation is made.

A 64 year old white woman, had a mole excised 12 years previously and presented with multiple rapidly progressing liver metastases. He received four treatment cycles of IL-2 and lymphokine activated killer cell cytokine therapy. After the third IL-2 cycle he developed severe low back pain and marked stiffness of the spine; the pain improved with motion. Clinical examination showed tenderness over the lumbar and sacral spine. Radiographs of the spine and sacroiliac joints were normal. Laboratory studies showed negative rheumatoid factors. During the fourth treatment he developed asymmetrical pain and swelling of shoulders and wrists, in addition. Symptoms resolved within four weeks of the end of the last treatment cycle. Twelve months later when he received a single five day IL-2 infusion as maintenance treatment the same symptoms recurred.

The second patient, a 44 year old white woman with a history of psoriasis, had had a few recurrent cutaneous lesions for more than 20 years. In the past two episodes of erythematous plaques had occurred. Ten years before treatment with IL-2 the primary tumour was excised. She presented with multiple subcutaneous and lymph node metastases; two months previously metastases in the stomach and the left adrenal gland had been resected. She received four treatment cycles comprising interferon and high dose continuous infusion of IL-2 for five days. After the second and third treatment cycles the patient had an exacerbation of psoriatic skin lesions and in the following treatment-free interval, she experienced transient arthritic pain of several finger joints. Three weeks after completion of the fourth treatment cycle she presented with sausage-like swelling of two fingers, and tendon metacarpophalangeal, proximal carpalphalangeal, and distal interphalangeal joints. Radiographs of the hands showed soft tissue swelling but no bony involvement. Rheumatoid factors were negative. Complete resolution of the symptoms occurred only several months after the last treatment cycle. After a maintenance treatment cycle 18 months later she again developed pain and sausage-like swelling of the right middle finger during the IL-2 infusion.

The two patients presented here had an excellent response to interferon therapy. In both patients the arthritis was self limited, with improvement when immunotherapy was stopped but could be reproducibly induced by successive treatment cycles. HLA typing of these patients showed the presence of HLA-B27 and HLA-B38, both major histocompatibility class II antigens associated with the respective diseases.

Several studies have reported the development of autoimmune thyroiditis in patients treated with IL-2 and lymphokine activated killer cells, 4 as well as without lymphokine therapy. 5-7 Recently, a rheumatoid arthritis-like disease was also seen in three patients after interferon alpha treatment. 8 Our observations provide further evidence that in subjects with autoimmune genetic predisposition activation of the immune system by biological response modifiers may trigger the clinical manifestations of autoimmune diseases.

CARMEN SCHEIBNENBEN
ULRICH KEILHOLZ
ANTONIO ZUCCOTTO
WERNER HÜNEST
Department of Internal Medicine V (Haematology/Oncology/Rheumatology)
University of Heidelberg Hospital 3
6900 Heidelberg, Germany


Immunosuppressive treatment in stroke and renal failure

Sir: We report on a patient who presented with acute stroke in association with polyarthritis nodosa (PAN), in whom an adequate and sustained renal response to immunosuppressive treatment was accompanied by recurrent ischaemic strokes recorded by computed tomography (CT) and magnetic resonance imaging. When considered with further evidence on the risks of stroke in PAN the case suggests that a more aggressive treatment regimen may be warranted in patients with cerebral disease.

A 43 year old man was admitted 16 hours after the sudden onset of true vertigo, which had been followed by left arm weakness and optic neuritis. Hypertension had been diagnosed four months previously after an episode of transient vertigo. There had been recurrent small and large joint arthropathy over the preceding 14 months. Anaemia had been noted over the blood transfusion centre for two occasions in the preceding 18 months. He had a normal intravenous urogram and barium enema following surgical admission with abdominal pain five months previously.

Clinical presentation showed widespread patchy pigmentation, fine crepitations at the lung bases, and evidence of recent weight loss. Partial (L) sided VII nerve palsy was present with minimal left alar nystagmus.

There was iron deficiency anaemia, haemoglobin 74 g/l, mean corpuscular volume 68.3 fl, with significant eosinophilia (0.48 x 10⁹/litre, 5% of white cell count). Urea was at the upper limit of normal (range 2-5-7.5) and creatinine was raised (145 μmol/I, normal range 60-110); creatinine clearance was reduced at 54 ml/min. Complement concentrations were normal apart from reduced CH50 at 126 Units (normal range 54-71). Serum antinuclear cytoplasmic antibody, hepatitis B surface antigen, and a screen for autoantibodies were negative. Blood pressure was 150/94 mmHg and remained unchanged during the admission. An electrocardiogram and chest radiograph were normal; pulmonary function tests showed moderately severe airflow obstruction and reduced gas transfer. Cerebral CT showed a small infarct in the region of the right basal ganglia. Transcranial Doppler sonography showed a generalised increase in blood flow velocities in the carotid and verteobasilar circulations, especially in the left middle cerebral artery (mean velocity 117 cm/s, normal 62,12 (mean SD)).

Daily testing showed deteriorating renal function (figure). Renal and hepatic angiography suggested PAN, and renal biopsy did not confirm the diagnosis. Cyclophosphamide (150 mg daily) and prednisolone (40 mg daily) was started, and renal function improved (figure). Three weeks later left arm power deteriorated and repeat CT showed new right hemisphere lesions. Further CT days later function in both arm and leg deteriorated; CT now showed a further temporoparietal infarct. Magnetic resonance imaging showed multiple ischaemic lesions in the right middle cerebral artery territory. The patient was transfused and heparin infusion started. Renal function did not deteriorate with the recurrent neurological episodes.

The patient was discharged at seven weeks with a mild left hemiparesis. His clinical condition and renal function remain stable eight months after his initial presentation.

The patient fulfils the clinical criteria for PAN. Both angiography and biopsy were positive and arterial lesions of different ages were seen, indicating a chronic cyclolical course rather than an acute onset.

Although diffuse cerebral ischaemia was suggested by the general increase in blood flow velocities, anaemia is likely to have contributed to the transcranial Doppler findings, 9 and intracranial artery to artery embolism might have caused the sequential strokes. Probably, however, the primary intracranial disease was arteritis. Moreover, there is evidence of a poor cerebrovascular response to immunosuppressive treatment in follow up studies of PAN; whereas early deaths are associated with
Rheumatic disease following immunotherapy.

C Scheibenbogen, U Keilholz, A Pezzutto and W Hunstein

Ann Rheum Dis 1993 52: 165
doi: 10.1136/ard.52.2.165-a

Updated information and services can be found at:
http://ard.bmj.com/content/52/2/165.1.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/